Wave Life Sciences to Present at Upcoming Investor Conferences
Wave Life Sciences (Nasdaq: WVE) announced that management will participate in two investor conferences in November 2025.
Guggenheim 2nd Annual Healthcare Innovation Conference — Paul Bolno, MD, MBA, President and CEO, will speak in an analyst-led fireside chat on Tuesday, November 11, 2025 at 10:00 a.m. ET.
Jefferies London Healthcare Conference — Dr. Bolno will join an analyst-led fireside chat on Thursday, November 20, 2025 at 8:30 a.m. GMT / 3:30 a.m. ET and participate in an Anti-Obesity Panel at 9:00 a.m. GMT / 4:00 a.m. ET. Live webcasts and limited-time replays are available via the company’s Investors "Investor Events" page.
Wave Life Sciences (Nasdaq: WVE) ha annunciato che la direzione parteciperà a due conferenze per investitori nel novembre 2025.
Guggenheim 2nd Annual Healthcare Innovation Conference — Paul Bolno, MD, MBA, Presidente e CEO, interverrà in un talk informale condotto da analisti martedì 11 novembre 2025 alle 10:00 a.m. ET.
Jefferies London Healthcare Conference — Il dottor Bolno parteciperà a un talk informale condotto da analisti giovedì 20 novembre 2025 alle 8:30 a.m. GMT / 3:30 a.m. ET e parteciperà a un Panel Anti-Obesità alle 9:00 GMT / 4:00 a.m. ET. Le dirette web e le repliche a tempo limitato sono disponibili tramite la pagina Investor Events degli investitori dell’azienda.
Wave Life Sciences (Nasdaq: WVE) anunció que la dirección participará en dos conferencias para inversionistas en noviembre de 2025.
Conferencia anual Guggenheim 2nd Healthcare Innovation Conference — El Dr. Paul Bolno, MD, MBA, Presidente y CEO, hablará en una charla informal dirigida por analistas martes 11 de noviembre de 2025 a las 10:00 a.m. hora del Este.
Conferencia londinense de atención médica Jefferies — El Dr. Bolno participará en una charla informal dirigida por analistas jueves 20 de noviembre de 2025 a las 8:30 a.m. GMT / 3:30 a.m. hora del Este y participará en un Panel Anti-Obesidad a las 9:00 GMT / 4:00 a.m. hora del Este. Las transmisiones en vivo y las repeticiones por un tiempo limitado están disponibles a través de la página de Inversores "Investor Events" de la empresa.
Wave Life Sciences (나스닥: WVE)는 경영진이 2025년 11월 두 차례의 투자자 컨퍼런스에 참여할 것이라고 발표했다.
Guggenheim 2nd Annual Healthcare Innovation Conference — Paul Bolno 박사, MD, MBA, 회장 겸 CEO가 애널리스트가 주도하는 Fireside Chat에 2025년 11월 11일 화요일 오전 10:00 ET에 발표한다.
Jefferies London Healthcare Conference — Dr. Bolno가 애널리스트가 이끄는 Fireside Chat에 2025년 11월 20일 목요일 오전 8:30 GMT / 동부 표준시 3:30에 참여하고 Anti-Obesity Panel에 9:00 GMT / 4:00 ET에 참여한다. 라이브 웹캐스트 및 제한 기간 재생은 회사의 투자자 페이지 Investor Events에서 이용 가능하다.
Wave Life Sciences (Nasdaq: WVE) a annoncé que la direction participera à deux conférences pour investisseurs en novembre 2025.
Guggenheim 2nd Annual Healthcare Innovation Conference — Le Dr Paul Bolno, MD, MBA, Président et PDG, participera à une discussion en tête-à-tête dirigée par des analystes mardi 11 novembre 2025 à 10h00 ET.
Jefferies London Healthcare Conference — Le Dr Bolno participera à une discussion dirigée par des analystes jeudi 20 novembre 2025 à 8h30 GMT / 3h30 ET et participera à un Panel Anti-Obésité à 9h00 GMT / 4h00 ET. Des webcasts en direct et des replays disponibles pendant une durée limitée sont accessibles via la page Investors "Investor Events" de l’entreprise.
Wave Life Sciences (Nasdaq: WVE) kündigte an, dass das Management im November 2025 an zwei Investorenkonferenzen teilnehmen wird.
Guggenheim 2nd Annual Healthcare Innovation Conference — Paul Bolno, MD, MBA, Präsident und CEO, wird in einem von Analysten moderierten Fireside-Chat am Dienstag, 11. November 2025 um 10:00 Uhr ET sprechen.
Jefferies London Healthcare Conference — Dr. Bolno wird an einem von Analysten moderierten Fireside-Chat am Donnerstag, 20. November 2025 um 8:30 Uhr GMT / 3:30 Uhr ET teilnehmen und an einem Anti-Obesity Panel um 9:00 Uhr GMT / 4:00 Uhr ET teilnehmen. Live-Webcasts und zeitlich begrenzte Replays sind über die Investorenseite des Unternehmens unter Investor Events verfügbar.
Wave Life Sciences (ناسداك: WVE) أعلنت أن الإدارة ستشارك في مؤتمرين للمستثمرين في نوفمبر 2025.
مؤتمر Guggenheim السنوي الثاني لابتكار الرعاية الصحية — سيتحدث الدكتور بولنو، MD, MBA، رئيس تنفيذي، في جلسة fireside يقودها المحللون الثلاثاء 11 نوفمبر 2025 الساعة 10:00 صباحاً بتوقيت شرق الولايات المتحدة.
مؤتمر Jefferies لندن للرعاية الصحية — سينضم الدكتور بولنو إلى جلسة fireside يقودها المحللون الخميس 20 نوفمبر 2025 الساعة 8:30 صباحاً بتوقيت GMT / 3:30 صباحاً بتوقيت شرق الولايات المتحدة وسيشارك في لوحة مكافحة السمنة الساعة 9:00 صباحاً بتوقيت GMT / 4:00 صباحاً بتوقيت شرق الولايات المتحدة. تتوفر البثوث المباشرة وإعاداتها لفترة محدودة عبر صفحة Investor Events للمستثمرين في الشركة.
- None.
- None.
CAMBRIDGE, Mass., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced that members of Wave’s management team are scheduled to participate in two upcoming investor conferences in November.
Guggenheim 2nd Annual Healthcare Innovation Conference
Date: Tuesday, November 11, 2025
Details: Paul Bolno, MD, MBA, President and CEO, will participate in an analyst-led fireside chat at 10:00 a.m. ET
Jefferies London Healthcare Conference
Date: Thursday, November 20, 2025
Details: Dr. Bolno will participate in an analyst-led fireside chat at 8:30 a.m. GMT / 3:30 a.m. ET and in the “Anti-Obesity Panel” at 9:00 a.m. GMT / 4:00 a.m. ET
Live webcasts of the analyst-led fireside chats can be accessed by visiting “Investor Events” on the Investors section of the Wave Life Sciences website: https://ir.wavelifesciences.com/events-publications/events. Replays of these events will be archived and available on the site for a limited time following the event.
About Wave Life Sciences
Wave Life Sciences (Nasdaq: WVE) is a biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health. Wave’s RNA medicines platform, PRISM®, combines multiple modalities, chemistry innovation and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and common disorders. Its toolkit of RNA-targeting modalities includes editing, splicing, RNA interference, and antisense silencing, providing Wave with unmatched capabilities for designing and sustainably delivering candidates that optimally address disease biology. Wave’s diversified pipeline includes clinical programs in obesity, alpha-1 antitrypsin deficiency, Duchenne muscular dystrophy, and Huntington’s disease, as well as several preclinical programs utilizing the company’s broad RNA therapeutics toolkit. Driven by the calling to “Reimagine Possible,” Wave is leading the charge toward a world in which human potential is no longer hindered by the burden of disease. Wave is headquartered in Cambridge, MA. For more information on Wave’s science, pipeline and people, please visit www.wavelifesciences.com and follow Wave on X and LinkedIn.
Contact:
Kate Rausch
VP, Corporate Affairs and Investor Relations
+1 617-949-4827
Investors:
James Salierno
Director, Investor Relations
+1 617-949-4043
InvestorRelations@wavelifesci.com
Media:
Katie Sullivan
Senior Director, Corporate Communications
+1 617-949-2936
MediaRelations@wavelifesci.com